Pain relief in osteoarthritis: Patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications

Journal of Rheumatology

Volumn 34, Issue 7, 2007, Pages 1569-1575

  Richardson, Chris G ^a,b   Chalmers, Andrew ^a   Llewellyn Thomas, Hilary A ^d   Klinkhoff, Alice ^a   Carswell, Anne ^c   Kopec, Jacek A ^b  

^a ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Adverse effects; Decision making; Osteoarthritis; Pain drug therapy; Patient acceptance of healthcare; Risk taking

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADULT; AGED; ANALGESIA; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT ATTITUDE; PATIENT PARTICIPATION; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH HEMORRHAGE; STROKE; THROMBOSIS;

AGED; ANTI-INFLAMMATORY AGENTS; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN; PATIENT ACCEPTANCE OF HEALTH CARE; RISK-TAKING;

EID: 34447525196     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343-55.
3. Badley EM, Wang PP. Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. J Rheumatol 1998;25:138-44.
4. Williams MH. Challenges for clinical decision making in the management of osteoarthritis of the knee. J Rheumatol 1996;23:586-9.
5. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995;38:1535-40.
6. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6.
7. Tannenbaum H, Davis P, Russell AS, et al. An evidence-based approach to prescribed NSAIDs in musculoskeletal disease; A Canadian consensus. CMAJ 1996;155:77-88.
8. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update. Arthritis Rheum 2000;43:1905-15.
9. Tannenbaum H, Peloso PMJ, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: the Second Canadian Consensus Conference. Can J Clin Pharmacol 2000;7 Suppl:4A-16A.
10. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57.
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
12. Health Canada. Report on the cardiovascular risks associated with COX 2 selective non-steroidal anti-inflammatory drugs. Ottawa: Health Canada Health Products and Food Branch; June 2006. Available from: http://www.hc-sc.gc.ca/dhp- mps/prodpharma/activit/sci-consult/cox2/cox2_cardio_report_rapport_e.html
13. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
14. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
15. Molenaar S, Sprangers MA, Postma-Schuit FC, et al. Feasibility and effects of decision aids. Med Decis Making 2000;20:112-27.
16. Emanuel EJ, Emanuel LL. Four models of the physician-patient relationship. JAMA 1992;267:2221-6.
17. Tannenbaum H. Patient empowerment: Rofecoxib revisited. J Rheumatol 2006;33:1033-1035.
18. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-6.
19. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000;43:378-85.
20. Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J. Patients' preferences for characteristics associated with treatments for osteoarthritis. Rheumatology Oxford 2004;43:337-45. Epub 2003 Oct 29.
21. Fraenkel L, Bogardus ST Jr, Concato J, Wittink DR. Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med 2004;164:1299-304.
22. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
23. Hawker J, Katz G, Solomon DJ. The patient's perspective on the recall of Vioxx. J Rheumatol 2006;33:1082-8.
24. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
25. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
26. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
27. Pirson Y, van Ypersele de Strihou C. Renal side effects of nonsteroidal antiinflammatory drugs: clinical relevance. Am J Kidney Dis 1986;8:338-44.
28. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-98.
29. Murray MD, Black PK, Kuzmid DD, et al. Acute and chronic effects of nonsteroidal anti-inflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995;310:188-97.
30. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making 1996;16:262-82.
31. Llewellyn-Thomas HA. Investigating patients' preferences for different treatment options. Can J Nurs Res 1997;29:45-64.
32. Llewellyn-Thomas HA, Paterson JM, Carter JA, et al. Primary prevention drug therapy: can it meet patients' requirements for reduced risk? Med Decis Making 2002;22:326-39.
33. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.